• Celerion Newsletter
Belfast - Center of Excellence for Respiratory

Celerion

committed to service excellence

Primary Navigation for Celerion

  • Home
  • About Celerion
    • Why Celerion?
    • Mission, Vision and Credo
    • Management Team
    • Who We Work With
    • Locations
    • Environmental Sustainability
  • Applied Translational Medicine
    • Key Elements of Success
  • Services
    • Global Clinical Research
      • AAHRPP Accreditation
      • Phase I and lla Studies
      • In-hospital Beds
      • Study Experience
      • Belfast – Center of Excellence for Respiratory
      • Early Cardiac Services
      • Hybrid Phase I/ECG Core Lab
      • ADME/Mass Balance
      • Microtracer Studies
      • USP <797> Clean Room
      • ClinQuick® Electronic Data Acquisition
      • Recruitment
    • Clinical Pharmacology Sciences
      • Modeling and Simulation
      • Study Design and Protocol Development
      • Data Programming
      • Biostatistics
      • Pharmacokinetics/Pharmacodynamics (PK/PD)
      • Medical Writing and Reporting
      • Streamlined Data Flow Process
    • Global Bioanalytical Services
      • Small Molecule
      • Large Molecule
      • Electronic Laboratory Notebook System
      • ADME/Mass Balance
    • Drug Development Services
      • Biopharmaceutical Development
      • Program and Project Management
      • Regulatory Affairs
  • Celerion Europe
    • Global Clinical Research
    • Clinical Pharmacology Sciences
    • Global Bioanalytical Services
    • Management Team
  • The Biosimilars Alliance
    • The Biosimilars Alliance – Overview
    • The Biosimilars Alliance – Benefits
  • Case Studies
    • Global Clinical Research
      • Responding to an Unexpectedly High Drop Rate
      • Mass Balance Study
      • Semen Clinical Trials
    • Clinical Pharmacology Sciences
      • Partnering with Biotechnology Companies
      • Partnering with Large Pharmaceutical Companies
      • Protocol Study Design and Development for Generic Studies
      • Difficult to Recruit Population
      • Consistent Database Structure for Programs of Studies
    • Global Bioanalytical Services
      • Improved Desmopressin Analysis of Clinical Samples
      • Optimized LC-MS/MS Method for New Observed Metabolite
      • Bioanalytical Support of Oncology Studies
      • High Throughput Bioanalytical Analysis
      • Partnering with Biotechnology Companies
      • Partnering with Pharmaceutical Companies
      • Development of an LC-MS/MS Peptide Method
    • Drug Development Services
      • Support of CMC to IND for Novel First-in-Class Small Molecule Drugs
      • Rapid Proof-of-Concept for Novel Drug Treatment for Rare Metabolic Disease
      • Proof-of-Concept Efficacy Clinical Study
      • European Biotechnology Company Seeking First-in-Human U.S. Clinical Study
      • Asian Biotechnology Company with CNS Compound
  • White Papers
  • Other Resources
  • News & Events
    • Press Room
    • Conferences
    • Symposia
    • Webinars
  • Participate in a Study
  • Careers
    • Message from the CEO
    • Culture
  • Spring 2013 Newsletter
  • Fall 2012 Newsletter
  • Spring 2012 Newsletter

Services

AAHRPP Accreditation

Celerion is the first CRO headquartered in the USA to achieve full accreditation from the Association for the Accreditation of Human Research Protection Programs (AAHRPP) for our clinical facilities in Lincoln NE, Neptune NJ and Phoenix AZ. This demonstrates the leadership role taken to reach the highest standards and protection for human participants in our clinical studies.

AAHRPP is an independent, non-profit accrediting body that uses a voluntary, peer-driven, educational model to ensure that Human Research Protection Programs (HRPPs) meet rigorous standards for quality and protection. To earn accreditation, organizations must provide tangible evidence—through policies, procedures, and practices—of their commitment to scientifically and ethically sound research and to continuous improvement.

The goals of accreditation are to:

  • Improve the systems that protect the rights and welfare of individuals who participate in research.
  • And communicate to the public the strength of an Organization’s commitment to the protection of human research participants.

To meet the full requirements for AAHRPP accreditation, Celerion reviewed all internal procedures and processes to build extensive safeguards into every level of clinical research. Throughout the organization our teams took an intensive and in-depth review of our policies, processes, and standard operating procedures (SOPs) to ensure they were well documented and rigorously translated into practice. The accreditation process lasted approximately 24 months, and included peer reviews and site audits from AAHRPP representatives.

AAHRPP accreditation is evidence of a quality research program. The AAHRPP seal indicates not only that an organization safeguards research participants but also that data are reliable and credible and the organization has made a commitment to continuous quality improvement.

For more information contact us

Footer Naviation

  • About
  • Locations
  • Careers
  • Request a Proposal
  • Contact
  • Privacy Policy
© 2013 Celerion